AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15593011
Drug: weekly CQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly CQ chemoprophylaxis
Trial: 15593011
Drug: 2-dose IPT
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose IPT with CQ
Trial: 11834680
Drug: Prednisone, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone, 60 mg/d for 7 days
Trial: 11207478
Drug: Gelatine 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatine 4% (GEL)
Trial: 11207478
Drug: Hydroxyethylstarch solution
RxNorm normalized name: hydroxyethylstarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethylstarch solution 6% (HES)
Trial: 9408699
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (750 mg twice a day for 3 months)
Trial: 8487654
Drug: Heparin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin administration prior to FSIGT
Trial: 8487654
Drug: Saline administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline administration prior to FSIGT
Trial: 3104750
Drug: TRH (thyrotropin-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH (thyrotropin-releasing hormone) at 10 mg per kg on alternate days for 3 months
Trial: 3102991
Drug: TRH (thyrotropin-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH (thyrotropin-releasing hormone)
Trial: 22315336
Drug: Adjuvanted 3.75-μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted 3.75-μg HA/AS03(A)
Trial: 22315336
Drug: Adjuvanted formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted formulation (2 doses) or 1 dose of adjuvanted 3.75-μg HA formulation
Trial: 14671904
Drug: Plapherone LB
RxNorm normalized name: spinosad
DrugBank: Spinosad (DB08823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plapherone LB (sublingually, 2 mg protein/day)
Trial: 14671904
Drug: Routine intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine intensive therapy
Trial: 10804025
Drug: Human parathyroid
RxNorm normalized name: HUMAN PARATHYROID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human parathyroid hormone 1-34 (hPTH(1-34)) daily injections for 12 months
Trial: 10804025
Drug: Human parathyroid
RxNorm normalized name: HUMAN PARATHYROID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human parathyroid hormone 1-34 (hPTH(1-34))
Trial: 8956699
Drug: Serum CA
RxNorm normalized name: Serum carnosinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum CA 125 concentration > or = 30 U/ml
Trial: 8956699
Drug: Serum CA
RxNorm normalized name: Serum carnosinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum CA 125 concentration > 100 U/ml
Trial: 8956699
Drug: Serum CA
RxNorm normalized name: Serum carnosinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum CA 125 concentration < 30 U/ml
Trial: 1658962
Drug: 1500 aPTT-U
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 aPTT-U low-molecular-weight heparin plus 0.5 mg dihydroergotamine (Embolex)
Trial: 1658962
Drug: twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily administration of 5000 IU of the heparin-dihydroergotamine combination (Heparin-Dihydergot)
Trial: 23838709
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (group T)
Trial: 20041778
Drug: Red ginseng
RxNorm normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red ginseng extract-containing herbal mixture at 3 g/day
Trial: 15764166
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg daily for 5 days, repeated 3 times with a 23-day interval
Trial: 2616205
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine-gum (8-12 gums a day for one month)
Trial: 310339
Drug: Combined adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined adjuvant immunotherapy (bacillus Calmette‐Guérin and levamisole)
Trial: 30587963
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for AECOPD
Trial: 25447602
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (LDK) infusion (0.2 to 0.4 mg/kg, administered over 10 to 15 minutes)
Trial: 25447602
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (LDK) infusion
Trial: 9264500
Drug: Perindoprilat (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindoprilat (5 nmol/mL)
Trial: 29405819
Drug: Rebound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebound therapy exercise (10-30 minutes, three sessions a week for 12 weeks)
Trial: 23657857
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) + L-NAME
Trial: 23657857
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) + L-NAME in DM
Trial: 23657857
Drug: Losartan (LOS)
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan (LOS) pretreatment + L-NAME in DM
Trial: 19192659
Drug: 20,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20,000 IU erythropoetin beta twice a week (group B)
Trial: 16875904
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy with the ARB valsartan
Trial: 31667693
Drug: Sterile carbon
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sterile carbon particle suspension (SCPS)
Trial: 28425497
Drug: Memantine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 20 mg (p.o.)
Trial: 23243228
Drug: Pleasant contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pleasant contact (PL) - chicks stroked gently for 30 s once daily from d 1 to 28
Trial: 23243228
Drug: Unpleasant contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unpleasant contact (UNPL) - chicks suspended by legs and exposed to noise for 15 s once daily from d 1 to 28
Trial: 23243228
Drug: PL and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PL and PL-UNPL treatments
Trial: 21991728
Drug: Ropivacaine 0.25%
RxNorm normalized name: ROPivacaine 0.25%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.25% and morphine 0.2 mg/mL
Trial: 21991728
Drug: Ropivacaine 0.25%
RxNorm normalized name: ROPivacaine 0.25%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.25% and morphine 0.2 mg/mL and Xefocam 0.8 mg/mL
Trial: 19960134
Drug: Diuretic-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic-based treatment (n=20)
Trial: 19960134
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker (CCB)-based treatment (n=18)
Trial: 16901484
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/d) for >or=3 weeks
Trial: 3042576
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg b.i.d. + placebo b.i.d.)
Trial: 23447607
Drug: DA antagonist
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA antagonist administration
Trial: 19825284
Drug: Dexamethasone (intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (intravenously once a day for 4 weeks, then orally once daily for another 4 weeks)
Trial: 19825284
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard anti-tuberculosis drugs only)
Trial: 9264417
Drug: Propranolol (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (8 mg cumulative dose or maximum heart rate reduction of 25%)
Trial: 29576125
Drug: PECs blocks
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PECs blocks (levobupivacaine 0.25%, 10 ml PECs I and 20 ml PECs II)
Trial: 29576125
Drug: LA infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LA infusion (levobupivacaine 0.1% at 10 ml h‐1 for 24 h)
Trial: 29576125
Drug: Both PECs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both PECs and LA infusion
Trial: 28410749
Drug: K-877 (pemafibrate)
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-877 (pemafibrate) 0.1, 0.2, and 0.4 mg/day in combination with pitavastatin for 12 weeks
Trial: 28410749
Drug: K-877 (pemafibrate)
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-877 (pemafibrate) 0.2 mg/day (fixed dose) and 0.2 (0.4) mg/day (conditional up-titration) in combination with any statin for 24 weeks
Trial: 28410749
Drug: K-877 add-on
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-877 add-on therapy
Trial: 28410749
Drug: K-877 combination
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-877 combination therapy
Trial: 16942565
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with tree pollen extract, accumulated weekly dose of 200,000 SQ-U, 5 days a week for up to 18 months
Trial: 16942565
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with tree pollen extract, accumulated weekly dose of 24,000 SQ-U, 5 days a week for up to 18 months
Trial: 8390528
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg once a day
Trial: 1390326
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg once a day
Trial: 11889776
Drug: Droperidol 2.5
RxNorm normalized name: droperidol 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 2.5 mg
Trial: 19294678
Drug: Oral azithromycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral azithromycin, 500 mg per day for 3 days before amniocentesis
Trial: 1413580
Drug: Drugs only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs only
Trial: 15100593
Drug: Oxcarbazepine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (150 mg/day, titrated to 1200 mg/day)
Trial: 15100593
Drug: Oxcarbazepine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (1200 mg/day during Maintenance Phase)
Trial: 11281158
Drug: hPTH plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hPTH plus hormone-replacement therapy (HRT)
Trial: 9397118
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (ERT) with 2 mg/day of oral micronized estradiol for 12 weeks
Trial: 25540980
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HP and LGI diets
Trial: 18626487
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine jelly
Trial: 12648114
Drug: Patient-maintained sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-maintained sedation using a target-controlled infusion of propofol
Trial: 1425899
Drug: alfentanil 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 15 micrograms.kg‐1, vecuronium 0.01 mg.kg‐1, thiopentone 3‐4 mg.kg‐1, suxamethonium 1 mg.kg‐1
Trial: 1425899
Drug: vecuronium 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vecuronium 0.01 mg.kg‐1, thiopentone 3‐4 mg.kg‐1, suxamethonium 1 mg.kg‐1
Trial: 4064558
Drug: Naloxone (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (intravenous administration)
Trial: 20711087
Drug: Passive removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive removal of silicone oil with 23-G transconjunctival sutureless system
Trial: 20711087
Drug: 20-G active
RxNorm normalized name: ubiquinol 20 MG/ML [Active Q]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-G active silicone oil removal using all three 20-G ports
Trial: 18652603
Drug: Adalimumab therapy
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab therapy (160 mg loading dose at week 0, 80 mg at week 2, 40 mg every other week starting at week 4)
Trial: 31867564
Drug: Adalimumab therapy
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab therapy
Trial: 15740542
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii (250 mg, orally, twice daily during antibiotic treatment)
Trial: 8777661
Drug: Commercial sweet-tasting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial sweet-tasting solution
Trial: 8777661
Drug: 25% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% sucrose solution
Trial: 11937721
Drug: 50% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% sucrose solution
Trial: 1610998
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's (LR) solution (group I)
Trial: 1610998
Drug: LR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LR with 5% dextrose solution (group II)
Trial: 6706438
Drug: pirbuterol 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pirbuterol 20 mg
Trial: 26197031
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg · d(‐1) for 6 months
Trial: 20233153
Drug: Weight maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight maintenance interventions following family-based behavioral weight loss treatment for HIGH children (n = 71)
Trial: 20233153
Drug: Weight maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight maintenance interventions following family-based behavioral weight loss treatment for LOW children (n = 130)
Trial: 29206136
Drug: Diascorea extracts
RxNorm normalized name: Dioscorea communis top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diascorea extracts (12 mg/dose, 2 sachets daily)
Trial: 25710190
Drug: Red Bull
RxNorm normalized name: acid red 35
DrugBank: Pantothenic acid (DB01783)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red Bull (9.4 mL/kg body mass containing 3 mg/kg body mass caffeine)
Trial: 25710190
Drug: Anhydrous caffeine
RxNorm normalized name: Anhydrous caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anhydrous caffeine (3 mg/kg body mass in capsule form)
Trial: 22137516
Drug: BIS‐guided target‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS‐guided target‐controlled infusion of propofol
Trial: 24817819
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% plus perineural dexamethasone 4 mg (group Dperi)
Trial: 24817819
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% plus intravenous dexamethasone 4 mg (group Div)
Trial: 16787138
Drug: PDE3 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDE3 inhibitors
Trial: 16787138
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with beta-adrenergic receptor antagonists
Trial: 12841882
Drug: Vaginal ring
RxNorm normalized name: NuvaRing Vaginal Ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal ring releasing estradiol acetate (50 microg/day) plus placebo tablets
Trial: 12841882
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol (1 mg/day) plus placebo vaginal ring
Trial: 8325043
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate via 'Autohaler' inhalation device
Trial: 8325043
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate via conventional metered dose inhaler
Trial: 3822496
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusion (5 mg/kg body weight)
Trial: 28611089
Drug: Free and
RxNorm normalized name: Free and Clear
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free and convenient access to a carefully selected list of 125 essential medicines (based on the WHO's Model List of Essential Medicines)
Trial: 28611089
Drug: Usual means
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual means of medicine access
Trial: 16543745
Drug: Substance misuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance misuse with psychiatric concurrent disorders
Trial: 14507560
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of 0.5% hyperbaric bupivacaine
Trial: 14507560
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of 0.5% hyperbaric bupivacaine
Trial: 14507560
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of 0.5% hyperbaric bupivacaine
Trial: 6844470
Drug: Weekly sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly sessions with one therapist
Trial: 6844470
Drug: Monthly sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly sessions with one therapist
Trial: 30221566
Drug: PRG-loaded NVTEs
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PRG-loaded NVTEs vaginal gel
Trial: 30286920
Drug: Less than
RxNorm normalized name: IgA less than or equal to 50 mcg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less than weekly hypoglycemia
Trial: 30286920
Drug: Greater than
RxNorm normalized name: immune globulin,alpha (IgA) greater than 50 mcg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater than or equal to weekly hypoglycemia
Trial: 26355167
Drug: 8.5 mm-long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.5 mm-long implants
Trial: 25124505
Drug: Group anger
RxNorm normalized name: After banger
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group anger management treatment (AMT)
Trial: 22011557
Drug: Ivabradine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine 15 mg
Trial: 22011557
Drug: Ivabradine in
RxNorm normalized name: Product containing ivabradine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine in long-term β-blocker therapy
Trial: 22011557
Drug: Metoprolol in
RxNorm normalized name: metoprolol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol in long-term β-blocker therapy
Trial: 17465661
Drug: Adper Prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt L‐Pop after one light cure
Trial: 17465661
Drug: Adper Prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt L‐Pop after two light cures
Trial: 17465661
Drug: SEP Adper
RxNorm normalized name: Asper-Flex
DrugBank: Trolamine salicylate (DB11079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SEP Adper Prompt L‐Pop
Trial: 15074085
Drug: Angelica Injection
RxNorm normalized name: Angelica
DrugBank: Angelica archangelica root (DB14283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angelica Injection (AI)
Trial: 15074085
Drug: Compound salvia
RxNorm normalized name: Salvia sclarea seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound salvia
Trial: 15074085
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular dextran injection
Trial: 2125546
Drug: Monophasic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic preparation (150 micrograms LNG and 30 micrograms EE)
Trial: 2125546
Drug: Triphasic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic preparation (low doses of LNG and EE in various proportions)